Compare QNCX & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNCX | MNDO |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 19.0M |
| IPO Year | 2019 | 2000 |
| Metric | QNCX | MNDO |
|---|---|---|
| Price | $0.99 | $1.00 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 466.1K | 51.2K |
| Earning Date | 04-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 20.95% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.34 | $8.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.85 |
| 52 Week High | $4.55 | $1.50 |
| Indicator | QNCX | MNDO |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 57.76 |
| Support Level | $0.88 | $0.89 |
| Resistance Level | $0.98 | $1.23 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 62.13 | 84.56 |
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.